Delix Therapeutics Awarded Grant from the U.S. Department of Defense to Advance Neuroplastogen for Hearing Loss
- Supports the development of a novel, non-hallucinogenic neuroplastogen to restore hearing by stimulating cochlear synaptic growth
- Reinforces the potential of Delix's proprietary neuroplasticity platform to identify neuroplastogens to treat a wide range of synapse-related disorders, beyond those associated with mental health conditions